The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
A. J. Weickhardt
Research Funding - Roche
D. Williams
No relevant relationships to disclose
C. Lee
No relevant relationships to disclose
J. Simes
Research Funding - Roche
C. Murone
No relevant relationships to disclose
K. Wilson
No relevant relationships to disclose
M. Cummins
Other Remuneration - Roche
K. Asadi
No relevant relationships to disclose
T. J. Price
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
J. Mariadason
No relevant relationships to disclose
N. C. Tebbutt
Consultant or Advisory Role - Roche (U)
Research Funding - Roche